Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 rusfertide study in polycythemia vera
NL-OMON53847Phase 3Recruiting
- Sponsor
- Protagonist Therapeutics, Inc.
- Start
- Aug 2023
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rusfertide in polycythemia vera (PV), sponsored by Protagonist Therapeutics, Inc. Started Aug 2023; status: recruiting.
02
Drugs
rusfertide
03
Conditions
polycythemia vera (PV)
Beyond the preview
Go deeper on NL-OMON53847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53847.